Deletion at Chromosome Arm 9p in Relation to BRAF/NRAS Mutations and Prognostic Significance for Primary Melanoma

Overview

Journal Genes Chromosomes Cancer

Specialties Molecular Biology
Oncology

Date 2010 Feb 9

PMID 20140953

Citations 17

Authors

Caroline Conway

Samantha Beswick

Faye Elliott

Yu-Mei Chang

Juliette Randerson-Moor

Mark Harland

Paul Affleck

Jerry Marsden

D Scott Sanders

Andy Boon

Margaret A Knowles

D Timothy Bishop

Julia A Newton-Bishop

Affiliations

Soon will be listed here.

Abstract

We report an investigation of gene dosage at 9p21.3 and mutations in BRAF and NRAS, as predictors of relapse and histological markers of poor melanoma prognosis. Formalin-fixed primary melanomas from 74 relapsed and 42 nonrelapsed patients were sequenced for common BRAF and NRAS mutations (N = 71 results) and gene dosage at 9p21.3 including the genes CDKN2A (which encodes CDKN2A and P14ARF), CDKN2B (CDKN2B), and MTAP was measured using multiplexed ligation-dependant probe amplification (MLPA), (N = 75 results). BRAF/NRAS mutations were detected in 77% of relapsers and 58% of nonrelapsers (Fisher's exact P = 0.17), and did not predict ulceration or mitotic rate. There was no relationship between BRAF/NRAS mutations and gene dosage at 9p21.3. Reduced gene dosage at MTAP showed a borderline association with BRAF mutation (P = 0.04) and reduced gene dosage at the interferon gene cluster was borderline associated with wild type NRAS (P = 0.05). Reduced gene dosage in the CDKN2A regions coding for CDKN2A was associated with an increased risk of relapse (P = 0.03). Reduced gene dosage across 9p21.3 was associated with increased tumor thickness, mitotic rate, and ulceration (P = 0.02, 0.02, and 0.002, respectively), specifically in coding regions impacting on CDKN2B and P14ARF and CDKN2A. Loss at MTAP (P = 0.05) and the interferon gene cluster (P = 0.03) on 9p21 was also associated with tumor ulceration. There was no association between reduced gene dosage at 9p21.3 and subtype or site of tumor. This study presents supportive evidence that CDKN2B, P14ARF, and CDKN2A may all play a tumor suppressor role in melanoma progression.

Citing Articles

Patterns of Aneuploidy and Signaling Consequences in Cancer.

Zhakula-Kostadinova N, Taylor A Cancer Res. 2024; 84(16):2575-2587.

PMID: 38924459 PMC: 11325152. DOI: 10.1158/0008-5472.CAN-24-0169.

Novel Biomarkers and Druggable Targets in Advanced Melanoma.

Ferrucci P, Cocorocchio E Cancers (Basel). 2022; 14(1).

PMID: 35008245 PMC: 8750474. DOI: 10.3390/cancers14010081.

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects.

Pilla L, Alberti A, di Mauro P, Gemelli M, Cogliati V, Cazzaniga M Cancers (Basel). 2020; 12(11).

PMID: 33233603 PMC: 7699774. DOI: 10.3390/cancers12113456.

Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.

Ming Z, Lim S, Rizos H Biomolecules. 2020; 10(10).

PMID: 33076392 PMC: 7602651. DOI: 10.3390/biom10101447.

A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation.

Giunti L, Da Ros M, De Gregorio V, Magi A, Landini S, Mazzinghi B Mol Clin Oncol. 2019; 10(3):331-338.

PMID: 30847170 PMC: 6388501. DOI: 10.3892/mco.2019.1795.

References

Bishop D, Demenais F, Goldstein A, Bergman W, Bishop J, Bressac-de Paillerets B . Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002; 94(12):894-903. DOI: 10.1093/jnci/94.12.894. View

Schouten J, McElgunn C, Waaijer R, Zwijnenburg D, Diepvens F, Pals G . Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30(12):e57. PMC: 117299. DOI: 10.1093/nar/gnf056. View

Straume O, Smeds J, Kumar R, Hemminki K, Akslen L . Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol. 2002; 161(1):229-37. PMC: 1850679. DOI: 10.1016/S0002-9440(10)64174-0. View

Kamb A, Gruis N, Liu Q, Harshman K, Tavtigian S, STOCKERT E . A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994; 264(5157):436-40. DOI: 10.1126/science.8153634. View

Peters G . Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma. J Natl Cancer Inst. 2008; 100(11):757-9. DOI: 10.1093/jnci/djn156. View

Cachia A, Indsto J, McLaren K, Mann G, Arends M . CDKN2A mutation and deletion status in thin and thick primary melanoma. Clin Cancer Res. 2000; 6(9):3511-5. View

Fujimoto A, Morita R, Hatta N, Takehara K, Takata M . p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene. 1999; 18(15):2527-32. DOI: 10.1038/sj.onc.1202803. View

Rodolfo M, Daniotti M, Vallacchi V . Genetic progression of metastatic melanoma. Cancer Lett. 2004; 214(2):133-47. DOI: 10.1016/j.canlet.2004.06.049. View

Gimotty P, Botbyl J, Soong S, Guerry D . A population-based validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2005; 23(31):8065-75. DOI: 10.1200/JCO.2005.02.4976. View

10.

Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J . Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res. 2009; 15(22):6939-46. PMC: 2778654. DOI: 10.1158/1078-0432.CCR-09-1631. View

11.

Talve L, Sauroja I, Collan Y, Punnonen K, Ekfors T . Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997; 74(3):255-9. DOI: 10.1002/(sici)1097-0215(19970620)74:3<255::aid-ijc4>3.0.co;2-y. View

12.

von Eggeling F, Werner G, Theuer C, Riese U, Dahse R, Fiedler W . Analysis of the tumor suppressor gene p16(INK4A) in microdissected melanoma metastases by sequencing, and microsatellite and methylation screening. Arch Dermatol Res. 1999; 291(7-8):474-7. DOI: 10.1007/s004030050440. View

13.

Zhao Y, Zhang Y, Yang Z, Li A, Dong J . Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 2008; 370(3):509-13. DOI: 10.1016/j.bbrc.2008.03.148. View

14.

Nygren A, Ameziane N, Duarte H, Vijzelaar R, Waisfisz Q, Hess C . Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005; 33(14):e128. PMC: 1187824. DOI: 10.1093/nar/gni127. View

15.

Goldstein A, Tucker M . Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol. 2001; 137(11):1493-6. DOI: 10.1001/archderm.137.11.1493. View

16.

Liu Y, Sanoff H, Cho H, Burd C, Torrice C, Mohlke K . INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One. 2009; 4(4):e5027. PMC: 2660422. DOI: 10.1371/journal.pone.0005027. View

17.

Takata M . Detection of copy number changes at multiple loci in DNA prepared from formalin-fixed, paraffin-embedded tissue by multiplex ligation-dependent probe amplification. Methods Mol Biol. 2008; 439:101-8. DOI: 10.1007/978-1-59745-188-8_7. View

18.

Krimpenfort P, Ijpenberg A, Song J, van der Valk M, Nawijn M, Zevenhoven J . p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature. 2007; 448(7156):943-6. DOI: 10.1038/nature06084. View

19.

Sharpless N, DePinho R . The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev. 1999; 9(1):22-30. DOI: 10.1016/s0959-437x(99)80004-5. View

20.

Michaloglou C, Vredeveld L, Soengas M, Denoyelle C, Kuilman T, van der Horst C . BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436(7051):720-4. DOI: 10.1038/nature03890. View